Relation of Serum ADMA, Apelin‐13 and LOX‐1 Levels with Inflammatory and Echocardiographic Parameters in Hemodialysis Patients

Doğan, İbrahim; Doğan, Tolga; Yeti̇m, Mücahit; Kayadibi, Hüseyin; Yilmaz, Mehmet Birhan; Eser, Barış; Kalçık, Macit; Karaveli̇oğlu, Yusuf

doi:10.1111/1744-9987.12613

Cited by 11 publications

(16 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding came in accordance with Dogan I et al, who stated that the increased serum LOX-1 in uremic patients is a constant finding. 25 Also, our findings came in agreement with Rashed et al, who reported that chronic renal failure and ESRD patients on regular hemodialysis have significantly increased in ADMA than do control subjects. 26 UgurcuV and his colleagues explained the significant increase of serum ADMA in patients on hemodialysis and chronic renal failure stage-4 by the higher levels of methylation of protein, increased rate of protein turnover moreover increased ADMA is due to its depressed excretion and decreased activity of DDAH enzymes that are used in its catabolism.…”

Section: Discussionsupporting

confidence: 93%

Serum LOX-1, ADMA and hs-CRP as Biomarkers of Ischemic Heart Disease in Chronic kidney Disease Patients

Nassar

Harfoosh

Aziz

et al. 2020

Al-Azhar International Medical Journal

View full text Add to dashboard Cite

Chronic renal disease is a worldwide major health problem, with increasing incidence, prevalence, high costs, and poor outcomes. 1 Mortality among patients with CKD and ESRD remains high due to its association with the occurrence of ischemic heart disease (IHD). 2 Numerous data show a close relationship between inflammation and cardiovascular morbidity and mortality. Hs-CRP is an important indicator and diagnostic tool for systemic inflammation. It has been found that Interleukin-6 and tumour necrosis factor-α are proinflammatory cytokines that can stimulate CRP synthesis in the liver. 3 All these biomarkers are very useful in the prediction of cardiovascular complications and mortality in ESRD patients. 4 Renal function impairment frequently leads to IHD. There are many traditional risk factors associated with IHD. Nowadays non-traditional CKD-specific risk factors for IHD appeared. Among the most important non-conventional risk factors are uremic toxins (UTs). Despite many studies either

show abstract

Section: Discussionsupporting

confidence: 93%

Serum LOX-1, ADMA and hs-CRP as Biomarkers of Ischemic Heart Disease in Chronic kidney Disease Patients

Nassar

Harfoosh

Aziz

et al. 2020

Al-Azhar International Medical Journal

View full text Add to dashboard Cite

show abstract

“…lower serum APLN levels than healthy individuals (Małyszko et al, 2006). On the contrary, the detection of serum APLN level in patients on HD and PD indicated that the level of APLN was higher than that in the normal population (Büyükbakkal et al, 2015;Dogan et al, 2018). The latest detection of serum APLN levels in patients with PD also indicated that APLN levels in this set of patients were higher than those in the normal population (Karaer Büberci et al, 2022).…”

Section: Discussionmentioning

confidence: 99%

“…However, the relationship between APLN and inflammation, which is known to promote EMT ( Li et al, 2014 ), has been studied. Some scholars suggested that APLN can evaluate inflammation and prevent the occurrence of atherosclerotic cardiovascular disease in patients undergoing both PD and HD ( Dogan et al, 2018 ; Trojanowicz et al, 2020 ; Karaer Büberci et al, 2022 ). However, some studies have also indicated that APLN induces the expression of inflammatory factors MCP-1, VCAM-1, and ICAM-1 in human umbilical vein endothelial cells by activating the NF-kB/JNK signaling pathway ( Trojanowicz et al, 2020 ).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Elabela Attenuates the TGF-β1-Induced Epithelial-Mesenchymal Transition of Peritoneal Mesothelial Cells in Patients Receiving Peritoneal Dialysis

Xie

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Peritoneal fibrosis (PF), a common complication in patients receiving peritoneal dialysis (PD), is primarily caused by the epithelial-mesenchymal transition (EMT) of human peritoneal mesothelial cells (HPMCs). PF is the main reason for patients on PD to withdraw from PD. Effective treatment is unavailable for this complication at present. Elabela (ELA) is a polypeptide hormone secreted by the vascular endothelium and kidney. Peptide hormones ELA and apelin (APLN) have various protective effects on the cardiovascular and urinary systems and have potential therapeutic effects on organ fibrosis. ELA and APLN are less studied in PD population. Here, we aimed to investigate the clinical significance of ELA in patients on PD and to evaluate the therapeutic effect of ELA on EMT of HPMCs. Compared with those in patients with stage 5 chronic kidney disease who are not on dialysis, serum ELA levels in patients on PD increased with the improvement of residual renal function at PD duration <36 months and decreased to pre-dialysis levels at PD duration ≥36 months, suggesting that dialysis duration is the main risk factor affecting serum ELA levels in patients on PD. In addition, serum APLN levels decreased in the early stage of PD and recovered to the pre-dialysis level with the prolongation of dialysis time. Notably, serum APLN levels were positively correlated with dialysis duration in patients undergoing PD. To establish the EMT model, we stimulated HPMCs using transforming growth factor-beta 1 (TGF-β1) in cell experiments performed in vitro. ELA-32 treatment reversed the TGF-β1-induced reduction in the expression of the epithelial cell marker and suppressed the expression of mesenchymal cell markers by inhibiting the phosphorylation of SMAD2/3, ERK1/2, and AKT. Therefore, our findings imply that ELA-32 can interfere with the EMT of HPMCs by inhibiting the activation of the TGF-β/SMAD2/3, ERK1/2, and AKT pathways, providing novel insights on the potential therapeutic use of ELA for treating PD-related PF.

show abstract

“…Some studies support the opinion that sitagliptin has a pleiotropic property that lowers blood pressure (BP) through one or more pathways that are not very clear. The most common opinion is that sitagliptin activates endothelial nitric oxide synthase (eNOS) and increases nitric oxide (NO) bioavailability that improves the disrupted balance of endothelium (9,10). Infi ltration of adhesion molecules into the arterial wall and a low level of infl ammation is another initial step in HT (1).…”

Section: Introductionmentioning

confidence: 99%

A new perspective on the pleiotropic blood pressure improvement effect of sitagliptin: downregulation of miRNA-155 and miRNA-21

Gul-Kahraman¹,

Serhatlioglu²,

Önalan³

et al. 2021

BLL

View full text Add to dashboard Cite

INTRODUCTION: Deterioration of vascular responses is the crucial event in the initiation of cardiovascular problems in hypertension (HT) and diabetes mellitus (DM). A well-known oral antidiabetic, sitagliptin, has pleiotropic effects besides improving glycemic state in type-2 DM. This study aimed to investigate the therapeutic effect of sitagliptin on blood pressure with previously unassessed parameters of well-known pathophysiological processes and especially at the microRNA (miRNA) level where there are many unknowns. METHODS: N-nitro-L-arginine methyl ester (L-NAME)-induced HT model was performed on nondiabetic male rats. Four groups (including 7 rats in each) were formed: normotensives, sitagliptin-treated, HT and sitagliptintreated HT. Asymmetric dimethylarginine (ADMA), intercellular adhesion molecule-1 (ICAM-1) and tyrosine hydroxylase (TH), HT related miRNAs were evaluated. In-vitro vessel responses were observed. RESULTS: L-NAME led to a signifi cant increase in blood pressure. Hypertensives exhibited signifi cantly increased contractile responses, consistent with increased ADMA, ICAM-1. Sitagliptin decreased TH levels but not statistically signifi cantly. The new side of the study was the miRNA-21 and miRNA-155 expressions were in line with other parameters in both the HT and sitagliptin-treated HT groups. CONCLUSION: Sitagliptin may control comorbidities, especially HT and introduces new targets to alleviate vascular responses. The new knowledge is; sitagliptin may show these effects through microRNAs (Tab. 2, Fig. 6, Ref. 46).

show abstract

Relation of Serum ADMA, Apelin‐13 and LOX‐1 Levels with Inflammatory and Echocardiographic Parameters in Hemodialysis Patients

Cited by 11 publications

References 32 publications

Serum LOX-1, ADMA and hs-CRP as Biomarkers of Ischemic Heart Disease in Chronic kidney Disease Patients

Serum LOX-1, ADMA and hs-CRP as Biomarkers of Ischemic Heart Disease in Chronic kidney Disease Patients

Elabela Attenuates the TGF-β1-Induced Epithelial-Mesenchymal Transition of Peritoneal Mesothelial Cells in Patients Receiving Peritoneal Dialysis

A new perspective on the pleiotropic blood pressure improvement effect of sitagliptin: downregulation of miRNA-155 and miRNA-21

Contact Info

Product

Resources

About